BioCentury
ARTICLE | Top Story

INHL drops on mixed data

June 25, 2001 7:00 AM UTC

Inhale (INHL) fell $7.62 (22%) to $27.03 on Monday after the company reported mixed data from a Phase III trial of its Exubera inhaled insulin in 299 patients. The company and its partners Pfizer (PFE) and Aventis (AVE) said the data showed Exubera plus one bed-time long-acting injection achieved target HbA1c levels of less than 7% in a greater proportion of patients compared to the injected insulin group. However, INHL said Exubera patients developed increased anti-insulin antibodies, which the company said did not appear to have any related clinical significance. Data showed that HbA1c levels decreased in both groups, and Exubera provided comparable glycemic control to the conventional insulin injections. INHL was up $3.35 (11%) to $34.65 on the week prior to the scheduled presentation yesterday. ...